Company Performance Metrics
Antony Loebel: Chief Medical Officer and President of Clinical DevelopmentPast Role: Sunovion Pharmaceuticals, President and Chief Executive Officer- Lana Gladstein: General Counsel
Seaport Therapeutics develops therapeutics for neuropsychiatric disorders, focusing on antidepressants and anxiolytics. The company utilizes its Glyph™ platform to create compounds designed for oral bioavailability while minimizing first-pass metabolism and reducing hepatotoxicity and other side effects. Its pipeline includes candidates that aim to
address underlying mechanisms of depression and anxiety, with ongoing research to optimize clinical efficacy and safety. Seaport Therapeutics also conducts meta-analyses and clinical studies to refine trial design and better understand factors influencing treatment outcomes. The company integrates pharmacological research with translational strategies to advance potential therapies from discovery through clinical development.
